¹Siti Mariam Maranata, ²Yunanto

^1,2Faculty of Law, Diponegoro University, Semarang, Indonesia Faculty of Law, Diponegoro University, Semarang, Indonesia

DOI : https://doi.org/10.47191/ijsshr/v8-i3-01

Google Scholar Download Pdf
ABSTRACT

TRIPS' patent policy limits the country's efforts in drug development, especially in the manufacture of generic drugs – drugs made after the patent period has expired. Patents greatly affect prices because they have a monopoly of ownership and require royalties from patent owners, such as rules about the selling price of drugs and the location of their distribution. The purpose of this study is to identify and study the licensing mechanisms necessary to protect public health access rights, COVID-19 vaccine patent filings in emergency situations, and COVID-19 vaccine patent waivers according to the Agremeent on Trade-Related Aspects of Intellectual Property Rights (TRIPs). The results of the study show that in an emergency, the mechanism for filing a patent for a Corona virus drug can be carried out based on the rules of Article 31 of the TRIPs Agreement, which allows the state to apply for a mandatory license or government use, especially in critical situations. This means that patents can be applied without the permission of the patent owner so that the Corona vaccine and drug are immediately made on a mass scale. The Government of Indonesia can use patents based on Patent Law No. 13 of 2016. In emergency situations, the government can patent without the permission of the patent holder. The United States can ignore COVID-19 vaccines as a progressive policy and encourage multilateral cooperation. Thus, developing countries must take advantage of this waiver to push for international reform of patent law to fulfill the right to public health.

KEYWORDS:

Patent Rights, Vaccines, Covid-19, TRIPs.

REFERENCES

A. Berita/Internet :
1) Hukum Online, 2017, https://www.hukumonline.com/klinik/a/peran-TRIPs-iagremeent-i-dalam-perlindungan- hakkekayaan-intelektual-lt592407520f6f7/

B. Buku :
1) Ali, Zainuddin. 2016. Metode Penelitian Hukum. Jakarta: Sinar Grafika

2) Asyhadie, Zaeni, 2012, Hukum Bisnis Prinsip dan Pelaksanaannya, PT RajaGrafindo Persada, Jakarta

3) Muhaimin. 2020. Metode Penelitian Hukum. Mataram: Mataram University Press

4) Soekanto, Soerjono. 2006. Pengantar Penelitian Hukum. Jakarta : UI Press

5) Suteki. 2020. Metodologi Penelitian Hukum (Filsafat, Teori dan Praktek), Depok: Rajawali Pers

C. Jurnal :
1) Atmaja, Yustisiana, dkk, 2021, “Pelindungan Hukum Terhadap Paten Produk Farmasi Atas Pelaksanaan Paten Oleh Pemerintah (Government Use)”, Jurnal Masalah- Masalah Hukum, Jilid 50 No. 2

2) Demmassabu, Valentino, 2017, “Penghapusan Lisensi Paten Oleh Pemegang Hak Paten Menurut Undang-Undang Nomor 13 Tahun 2016 Tentang Paten,” Jurnal Lex Privatum, Vol. 5 No. 2

3) Hafsar, Yuliana Maulida, 2021, “Hak Atas Kekayaan Intelektual, Hak Merek, Rahasia Dagang, Dan Pelanggaran Hak

4) Merek Dan Rahasia Dagang Serta Hak Patent”, Jurnal Dinasti Review, Vol.2 No.6

5) Masnun, M. A dan Roszana, 2019, “Persoalan Pengaturan Kewajiban Pemegang Paten untuk Membuat Produk atau Menggunakan Proses di Indonesia”, Jurnal Hukum Ius Quia Iustum, Vol. 26 No. 2

6) Maria, Nisa dkk, 2022, “Pelaksanaan Pelayanan Farmasi Klinik di Apotek Pada Masa Pandemi COVID-19: Suatu Literature Review”, Saintech Farma: Jurnal Ilmu Kefarmasian, Vol. 15 No.1.

7) Muis, Lidya Shery 2019, “Hak Atas Aksesibilitas Obat Paten Bagi Masyarakat”, Jurnal Pranatam Vol. 2, No. 1 7) Noviarty, Helisa dan Yuniarsih Edryani, 2021, “Dampak Pandemi Covid-19 Terhadap Pengungkapan Tanggung Jawab Sosial Pada Sektor Farmasi”, Jurnal Audit dan Akuntansi Fakultas Ekonomi, Vol. 10 No. 2.

8) Pertiwi, Evi Darma, 2022, “Pelindungan Hak Akses Kesehatan Atas Perubahan Ketentuan Lisensi-Wajib Dalam UndangUndang Cipta Kerja”, Jurnal Lex Renaissance, Vol. 7 No. 1

9) Purba, Achmad Zen, 2004, “TRIPs dan Negara-Negara Berkembang”, Jurnal Hukum Internasional, Vol. 1 No. 2

10) Raharjo, Raden Bagoes dan Kholis Roisah, 2021, “Hak Akses Kesehatan Masyarakat Terhadap Hak Paten Produk Farmasi”, Jurnal USM Law Review, Vol. 4 No. 2.

Volume 08 Issue 03 March 2025